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Abstract
Deregulation of α-synuclein encoding gene (SNCA) is one of the important facets of Parkinson’s disease (PD) research.
DNA methylation status of SNCA-intron1 has been shown to regulate the α-synuclein expression. The present study is
aimed at investigating whether methylation of SNCA-intron1 is associated with higher expression of α-synuclein in PD.
We have investigated the intron1 methylation status from 16 post-mortem brain samples comprised of 8 PD and 8
control subjects using bisulfite sequencing. We further correlated this methylation status with α-synuclein protein levels
in substantia nigra of that individual using western blot analysis. We did not observe any significant difference in
methylation of SNCA-intron1 region between PD and control samples. Moreover, no correlation was observed between
methylation of SNCA-intron1 with α-synuclein level. Methylation of SNCA-intron1 region does not correlate with
α-synuclein expression in PD samples.
Keywords: Epigenetic regulation, DNA methylation, Parkinson’s Disease, α-synuclein
Introduction
Role of α-synuclein (α-SYN) in the pathogenesis of
Parkinson′s disease (PD) is undeniable. Epigenetic regu-
lation of α-SYN encoding gene (SNCA) has been greatly
explored focusing on the methylation status of intron1
CpG island [1–9]. SNCA harbors 6 exons of which two
upstream exons (1A and 1B) remain non-coding and
part of its 5′ untranslated region [1]. This intron1 region
right before the first coding exon (exon 2) has been
shown to regulate gene expression to a great extent by
differential methylation of its CpG island and also by re-
cruitment of several transcription factors [1, 10]. It is
known that SNCA duplication/triplication is strongly as-
sociated with familial form of PD and this gene multipli-
cation has also been shown to produce significantly
higher mRNA in the cell [11–13]. Thus it can be con-
ferred that higher expression of α-SYN can lead to PD
pathogenesis. Since hypomethylation of CpGs of a gene-
regulatory region is generally associated with increased
expression of the gene, it is hypothesized that decrease
in methylation in the intron1 of SNCA might increase
expression of α-SYN in PD [1]. In the present study, we
have investigated the methylation status of the SNCA-in-
tron1 in the substantia nigra of post-mortem PD pa-
tients and matched controls to decipher the association
of DNA methylation in this region and PD pathogenesis.
Moreover, we have also correlated this methylation sta-
tus with the level of α-SYN in the subjects.
Methods
Post-mortem brain samples
In the present study, 16 post-mortem brain samples were
investigated which consisted of 8 PD and 8 control subjects.
The 7 samples from each group were obtained from NIH
Neurobio bank consortium. Age ranged from 73 to 83 years
(average 78.71 years) and post-mortem interval (PMI) var-
ied from 6.7 hours to 15 hours (average 11.67 hours) in PD
cases. Similarly, the age of the controls ranged from 54 years
to 89 years with an average of 73.53 years. PMI for the con-
trols varied from 10 hours to 30.25 hours (average
24.02 hours). One control and PD brain sample were pro-
cured from UK Brain bank. Age and post-mortem delay in-
formation for those two subjects were not available to us.
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SNCA methylation analysis
Around 25 mg of SN tissue from each freshly frozen
sample was precisely isolated by punch biopsy. DNA was
extracted using Quick-DNA Universal Kit (Zymo Research;
Catalogue No. D4068). Around 500 nanograms of DNA
per sample was used for sodium bisulfite conversion using
EZ DNA methylation kit (Zymo Research; Catalogue No.
D5001) with little modifications following their
optimization guide to ensure complete bisulfite conversion.
Each reaction was made in duplicate to increase the
amount of template DNA for the PCR. To amplify the in-
tron1 region of SNCA spanning 23 CpG sites, we used the
primers as described by Jowaed et al. [1]. EpiMark Hot Start
Taq DNA polymerase (NEB Inc; Catalogue No. M0490S)
was used for the PCR amplification. The amplified PCR
products of 444 base pair (Fig.1a) were then cloned into
pGEM-T Easy vector (Promega; Catalogue No. A137A)
and 9 to 10 positive colonies per PCR product were se-
quenced using T7 promoter or SP6 reverse primers.
Western blot analysis
Protein level of α-SYN from each sample was analyzed
using 25-30 mg of freshly frozen SN tissue. Lysis was done
in 100 μL of RIPA buffer (Radio Immuno Precipitation
Assay buffer; 1% NP-40; 0.5% Sodium deoxycholate; 0.1%
SDS, supplemented with protease inhibitor) at 4 °C. Equal
amount of protein was loaded for all the samples in a 12%
SDS-polyacrylamide gel and the separated proteins were
then transferred onto a nitrocellulose membrane. The α-
SYN and β-actin protein bands were detected using spe-
cific primary antibodies (α-SYN, BD Transduction
Laboratories catalogue No. 610787, dilution 1: 500 and β-
actin, Sigma, Catalogue No. A5316, dilution: 1:10,000). An
anti-mouse HRP (Horse radish peroxidase)-conjugated
secondary antibody (Jackson Immuno Research, dilution
1:5,000) was used to visualize the bands by enhanced
chemiluminescent technique. Since, the two samples from
UK brain bank were collected in 2011, there was not
enough protein samples available at the time of study.
Therefore, those two samples were not included for the
studies on α-SYN protein level.
Statistical analysis
To calculate the relative level of methylation between
PD and control subjects, QUMA software was used for
the analysis with criteria that filters out the clonal PCR
sequences and analyses only unique clones of the sample
[14]. To determine the amount of methylation for each
Fig. 1 Methylation of SNCA-intron1 does not differ between PD and controls. SNCA contains 6 exons. A 444 bp region in the intron1 (-483 to
-926 bp with respect to ATG) was investigated. The sequence of the studied region is shown and the 23 CpGs are marked by numbers. The
priming regions are underlined (a). Relative level of methylation (b) and unmethylated CpG (c) between control (CTRL) and PD groups are shown.
No significant difference was observed between two groups for mean methylation level. Analysis of individual CpG site was done from control (n
= 8) and PD (n = 8) subjects (d). Analysis did not reveal any significant difference between the groups. For every subject, 9 to 10 clones were
studied to get the mean methylation percentage. The data is represented as mean ± SEM. Pair-wise comparison was made by Mann-Whitney
t-test to analyze the significance. n.s. represents non-significant difference
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individual at 23 different CpG sites, percentage methyla-
tion of each of the CpG site of those 9 to 10 clones were
calculated and averaged. Non-parametric Mann-
Whitney t-test was applied to assess the significant dif-
ference in the mean methylation level between control
and PD. Difference in normalized α-SYN expression (α-
SYN/β-actin) between the groups was measured using
Mann-Whitney t-test. To determine the correlation be-
tween percentage-demethylation with α-SYN expression,
non-parametric Spearman′s Rank correlation was used
for the groups followed by linear regression analysis. All
the statistical analyses and graphical representations
were done using GraphPad Prism software version 5.0.
Significance was assessed at 95% level. Data are pre-
sented as mean ± SEM.
Results
In the present study, SNCA-intron1 region is compar-
ably hypomethylated both in control (3.17 ± 0.66%) and
PD (3.04 ± 0.81%) samples, and there is no significant
difference in the methylation level between the groups
(p = 0.9) (Fig.1b and c). We have also explored the mean
methylation of individual CpG site (Fig. 1a and d). Pair-
wise comparison of each CpG also did not reveal any
significant difference in methylation between PD and
control (Fig. 1d). The α-SYN protein level, although
higher in PD cases, did not demonstrate any significant
difference when compared to controls (p = 0.26) (Fig. 2a).
At the same time, we did not observe any significant
correlation between amount of unmethylated CpG and
α-SYN expression in any group (r = -0.20, p = 0.67 con-
trol and r = 0.05, p = 0.92 PD) (Fig. 2b and c).
In the present cohort of samples, we did not find any
significant correlation between either age (r = 0.39, p =
0.39 for controls; r = 0.10, p = 0.83 for PD) or PMI (r
= -0.07, p = 0.89 for controls; r = 0.25, p = 0.59 for PD) of
the study subjects with respective methylation status using
Spearman′s rank correlation test. It was also previously
shown by de Boni et al., that there is no correlation be-
tween PMI and methylation in Lewy Body disease (LBD)
cases or in control [3]. However, they found a slightly sig-
nificant correlation with age of the LBD cases and methy-
lation [3].
Discussion
Regulation of SNCA expression by its methylation status of
inton1 has been widely studied in relation to PD [1–9]. It′s
important to note that SNCA like any other gene has sev-
eral regulatory regions and variations, which have been
shown to regulate this gene′s expression significantly irre-
spective of methylation status of SNCA-intron1 [15–17].
However, it’s also interesting that SNCA- intron1 methyla-
tion varies widely in different type of cells and demethyla-
tion of this region is positively correlated with higher
Fig. 2 Methylation status of SNCA-intron1 does not correlate with α-SYN level. Total α-SYN level was measured for both control (n = 7) and PD (n = 7)
groups using western blot analysis. The gel picture shows the level of α-SYN and β-actin in each samples, where C1 to C8 represent controls and P1 to
P8 represent the PD subjects respectively. The α-SYN level was compared between both the groups after normalizing it to respective β-actin. No
significant difference in α-SYN levels was observed between control and PD using Mann-Whitney t-test (a). Correlation between percentage of
demethylation with α-SYN levels for control (b) and PD patients (c) were carried out. The test did not reveal any significant correlation in any group
with α-SYN levels. Spearman’s rank correlation analysis was applied in both the groups. n.s. represents non-significant difference
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Table 1 List of different studies investigated on SNCA-intron1 methylation
Author group Tissues
studied
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PD, n = 6 controls),
putamen (n = 6 PD, n
= 8 control)















SN (n = 3 PD, n = 1
DLB, n = 3 control) ,
anterior cingulate
cortex (n = 12 PD/DLB,
n = 8 control),
putamen (n = 7 PD/
DLB, n = 4 control)
13 CpG sites





Not studied Hypomethylated only
in SN
Not studied






SN (n = 10 LBD, n = 3
control), putamen (n =
15 LBD, control n = 6),
cingulate gyrus (n = 15
LBD, n = 6 controls),
temporal cortex (n = 15
LBD, n = 6 controls),
cerebellum (n = 14
LBD, n = 6 controls)
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Not studied Hypomethylation Not studied
Richter et al.,
2012 [5]
PBMC Idiopathic PD (n = 43),
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controls (n = 37)






Not studied No significant change Not studied
Tan et al.,
2014 [6]
PBMC PD (n = 50), control
(n = 49)
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(n = 50)
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Ai et al., 2014
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PBMC PD (n = 100), control
(n = 95)
23 CpG sites Bisulfite/Sanger
sequencing
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36 control), cortex (n =




















PD Parkinson’s disease, SNpc Substantia nigra pars compacta, LBD Lewy body diseases, PBMC Peripheral blood mononuclear cells, Number of subjects are only
related to SNCA-intron1 methylation studies
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expression of α-SYN [1, 2]. Therefore, it is important to
study SNCA-intron1 methylation status in the SN of PD
and control to understand if hypomethylation of this gene
can be correlated with the disease.
In the present report, we have explored the methylation
status of SNCA-intron1 in the SN of post-mortem PD and
control subjects. As reported by others [1, 3, 6, 7], we also
have observed that mean methylation of this locus in the
SN is extremely low (Fig. 1c). We have studied a region of
intron1 which was previously studied by Jowaed et al. [1],
encompassing 23 CpG sites (Fig. 1a). We did not find any
significant hypomethylation in PD subjects as compared
to the controls (Fig. 1c). No association of SNCA-intron1
methylation in PD subjects was previously reported by
other groups as well [3, 5, 7]. However, several groups re-
ported significant difference in methylation between PD
and control [1, 2, 4, 6, 8, 9]. This apparent difference in
the outcome could be attributed to several factors like in-
vestigation of different CpGs regions in different studies,
admixture of different cell types in the SN region apart
from dopaminergic neurons and also may be due to differ-
ence in the sample characterization. Previously it was
shown using luciferase reporter assay, that a significant
demethylation of SNCA-intron1 could lead to an increase
in α-SYN expression as compared to the completely meth-
ylated one [1]. Similarly, HEK293 cells treated with dopa-
mine demonstrated induction of a sizable amount of
demethylation (94.4% to 21.2% methylation) in this region
and increased α-SYN expression [2]. Most of the studies
on human brain samples including the present one have
reported that SNCA-intron1 region in the SN is signifi-
cantly hypomethylated (≥90%) both in control and PD
which might be responsible for the constitutive expression
of α-SYN in both groups. So, it can be envisaged that a
small difference in methylation of SNCA-intron1 between
PD and control, might have a limited effect on further ex-
pression of α-SYN [8]. Since, methylation of individual
CpG site also can play a role in transcription factor
binding [1, 3, 6–8], we have examined all 23 CpG sites
separately in both the groups but failed to find any signifi-
cant difference (Fig. 1d). However, we observed that 2nd to
7th CpG sites have a trend of hypomethylation in PD
(Fig. 1d). Two other groups found significant differences
in some of the CpG sites in PD cases which they hypothe-
sized to play a significant role in increased transcription of
SNCA [1, 8]. On the other hand, another study couldn’t
find any site-specific hypomethylation in intron1 when
they studied different brain regions, instead they found
hypermethylation of few CpGs in some tissues in specific
stages of LBD (Table 1) [3]. Some studies reported a differ-
ence in intron1 methylation between PD and controls
from PBMC (peripheral blood mononuclear cells), how-
ever, some studies failed to find any such difference [5–8].
It has been already shown that methylation status varies
between tissues and not necessarily mimics the situation
in brain cell types [1, 2, 5–9].
Concurrently, we have also investigated α-SYN levels in
these two groups but as expected, failed to find any signifi-
cant difference in the protein level (Fig. 2a). However, both
groups contained high as well as low α-SYN expressing
subjects. This overall non-significant difference in protein
levels between the groups might be partially explained by
the observed non-significant difference in DNA methyla-
tion. One group showed a positive correlation between
decreased intron1 methylation with increased α-SYN ex-
pression in PD cases [6]. However, two other studies re-
ported no difference in α-SYN expression between PD and
controls but they found a significant hypomethylation in in-
tron1 [8, 9]. This further points out a limited effect of in-
tron1 methylation on overall α-SYN level or transcription.
Together, our study demonstrates a lack of association
between SNCA-intron1 methylation and PD. However,
this study points out the importance of studying a com-
prehensive epigenetic regulation of α-SYN rather than
focusing only on DNA methylation status of this gene.
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